Study of TNFR:Fc (Enbrel) in the Treatment of Asthma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The proposed study is a phase II clinical trial of TNFR:Fc therapy in a segmental allergen
bronchoprovocation model of atopic asthma. The goal of this study is to assess whether
inhibition of tumor necrosis factor (TNF) bioactivity can attenuate airway inflammation in
mild-to-moderate allergic asthmatics. This protocol will utilize a randomized, double-blind,
placebo-controlled trial design. TNF bioactivity will be inhibited via systemic
administration (e.g., subcutaneous injection) of a dimeric fusion protein consisting of the
extracellular ligand binding domain of the 75-kilodalton TNF receptor linked to the Fc
portion of human IgG1 (TNFR:Fc, Immunex). The data generated by this study will address the
utility of anti-TNF therapy for patients with asthma.